Product Description
Recently, the TIM-3 monoclonal antibody BC3402 injection developed by the company has obtained two clinical research approvals from the US Food and Drug Administration (FDA) and the National Medical Products Administration (NMPA). FDA approved the phase I clinical study of BC3402 injection in the United States for the treatment of malignant blood diseases (including myelodysplastic syndrome and chronic myelomonocytic leukemia, etc.), and China approved BC3402 injection combined with demethylation drugs Chemotherapy drugs are intended to be used in phase Ib/II clinical studies for the treatment of malignant blood diseases (including but not limited to myelodysplastic syndrome, acute myeloid leukemia, chronic myelomonocytic leukemia, etc.). The company will launch these two clinical studies in China and the United States in the near future. (Sourced from: https://mp.weixin.qq.com/s/KL5JWbCwlfXEjNI5PDle6Q)
Mechanisms of Action: HAVCR2 Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: BioCity
Company Location: Europe
Company Founding Year: 2002
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hepatocellular Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06111326 |
BC3402-105 | P2 |
Not yet recruiting |
Hepatocellular Carcinoma |
2024-08-01 |
30% |
2023-11-02 |
Primary Endpoints|Treatments |